Phospho-BCL9L (Ser915) Antibody

• 产品编号：CST-13325S      品牌：CST       原厂货号：13325S
• 产品分类：抗体 > 一抗 > 磷酸化抗体
• 应用分类：

描述：

Phospho-BCL9L (Ser915)抗体可以识别Ser915磷酸化的BCL9L蛋白。此多抗由合成肽段免疫动物产生，该肽段与人BCL9L蛋白Ser915邻近的氨基酸残基序列一致。抗体由蛋白A和肽段亲和层析技术纯化得到。B-cell CLL/lymphoma 9-like蛋白(BCL9L, BL2, Bcl9-2, DLNB11)是一类转录激活因子，最初发现它和BCL9同源被认为是 in silico(1)。随后发现BCL9L在Wnt/β-catenin信号通路中通过和β-catenin结合，增强β-catenin/TCF复合物的转录激活潜能而发挥了重要作用(2)。研究表明BCL9L在某些情况下增加异常的Wnt信号导致的结直肠癌的致瘤性(2)。BCL9L的表达与结直肠(3)和乳腺癌(2)中的癌症密切相关。在肠上皮中靶向敲除BCL9和BCL9L会导致Wnt靶基因被破坏，包括控制上皮-间质转换和干细胞样活性的基因(5)。此Phospho-BCL9L (Ser915)抗体是由于Cell Signaling Technology (CST)使用PhosphoScan^®和 CST's LC-MS/MS 平台的发现蛋白修饰点而设计的。Ser915的磷酸化是通过一个AMPK底物抗体发现的，并在多种细胞系中发现可以被胰岛素刺激诱导表达。请访问www.phosphosite.org上的CST's修饰位点网站－PhosphoSitePlus^®，以获得更多的信息。

1. Katoh, M. and Katoh, M. (2003) Int J Mol Med 12, 643-9.
2. Adachi, S. et al. (2004) Cancer Res 64, 8496-501.
3. Sakamoto, I. et al. (2007) Cancer Sci 98, 83-7.
4. Toya, H. et al. (2007) Cancer Sci 98, 484-90.
5. Deka, J. et al. (2010) Cancer Res 70, 6619-28.

原厂资料：

Homology

Species predicted to react based on 100% sequence homology: Mouse, Rat

Specificity / Sensitivity

Phospho-BCL9L (Ser915) Antibody recognizes endogenous levels of BCL9L protein only when phosphorylated at Ser915.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ser915 of human BCL9L protein. Antibodies are purified by protein A and peptide affinity chromatography.

Background

B-cell CLL/lymphoma 9-like protein (BCL9L, BL2, Bcl9-2, DLNB11) is a transcriptional activator that was originally identified in silico based on homology to BCL9 (1). BCL9L was subsequently found to play an important role in Wnt/β-catenin signaling by interacting with β-catenin and enhancing the transactivation potential of the β-catenin/TCF complex (2). Research studies show that BCL9L can increase the tumorigenic effect of aberrant Wnt signaling in some cases of colorectal cancer (2). Expression of BCL9L is correlated with tumor progression in colorectal (3) and breast cancer (4). Targeted deletion of BCL9 and BCL9L in the intestinal epithelium resulted in abrogation of Wnt target genes, including those controlling epithelial-mesenchymal transition and stem-cell like properties (5).Phospho-BCL9L (Ser915) Antibody is directed at a site that was identified at Cell Signaling Technology (CST) using PhosphoScan^®, CST's LC-MS/MS platform for modification site discovery. Phosphorylation at Ser915 was discovered using an AMPK substrate antibody. Please visit PhosphoSitePlus^®, CST's modification site knowledgebase, at www.phosphosite.org for more information.

1. Katoh, M. and Katoh, M. (2003) Int J Mol Med 12, 643-9.
2. Adachi, S. et al. (2004) Cancer Res 64, 8496-501.
3. Sakamoto, I. et al. (2007) Cancer Sci 98, 83-7.
4. Toya, H. et al. (2007) Cancer Sci 98, 484-90.
5. Deka, J. et al. (2010) Cancer Res 70, 6619-28.

注意事项：

Storage: Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM
NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C.
Do not aliquot the antibody.